Listen Top Shows Blog

18: Tackling performance requirements in the more prescriptive world of IVDR

18: Tackling performance requirements in the more prescriptive world of IVDR

Update: 2023-04-05

Share

Description

Summary:

IVD manufacturers must perform two types of performance studies, clinical performance and analytical performance, in order to provide evidence that the device is safe and performs as intended.

While both have always been required, IVDR is a lot more prescriptive.

Speaker:

Keely So is Manager, Medical Devices / IVD at PharmaLex, leveraging her extensive knowledge of the regulatory requirements in Australia, Europe, New Zealand, the USA, Canada and Asia to help clients with new product licensing and launch, regulatory impact and gap assessments, CE marking of devices and IVDs, ongoing product compliance initiatives and audit support.

Links:

https://www.pharmalex.com/pharmalex-industry-sectors/medtech/

Comments

In Channel

37: Optimizing revenue from mature products

37: Optimizing revenue from mature products

2025-07-1809:22

36: What’s happening with eCTD 4.0: New and future developments

36: What’s happening with eCTD 4.0: New and future developments

2025-07-1820:47

35: Challenges and best practices for managing local pharmacovigilance activities

35: Challenges and best practices for managing local pharmacovigilance activities

2025-05-0901:00

34: Environmental Risk Assessment and its growing importance in the German Pharma Strategy

34: Environmental Risk Assessment and its growing importance in the German Pharma Strategy

2025-04-1420:31

33: Finding the best approach to manage sterility assurance

33: Finding the best approach to manage sterility assurance

2025-01-2715:02

32: Commercialization Readiness

32: Commercialization Readiness

2024-11-0413:10

31: Key Steps for Site Inspection Readiness

31: Key Steps for Site Inspection Readiness

2024-06-2717:45

30: CSS Overview

30: CSS Overview

2024-05-0914:42

29: Exploring the interactions between validation and technology transfer

29: Exploring the interactions between validation and technology transfer

2024-01-2413:28

28: Early access programs: What they are and how to plan for them

28: Early access programs: What they are and how to plan for them

2023-12-0515:21

27: Assessing gaps and achieving compliance with Annex 1

27: Assessing gaps and achieving compliance with Annex 1

2023-11-2815:39

26: Navigating the Process of Technology Transfer

26: Navigating the Process of Technology Transfer

2023-11-1418:29

25: Scaling Patient Safety through Innovation

25: Scaling Patient Safety through Innovation

2023-09-2516:38

24: Why Early Phase Modeling is Key to Reimbursement and Patient Access

24: Why Early Phase Modeling is Key to Reimbursement and Patient Access

2023-09-1211:46

23: The Unique and Complex World of Combination Products

23: The Unique and Complex World of Combination Products

2023-08-3110:28

22: Avoiding Pitfalls with your Product Development Strategy

22: Avoiding Pitfalls with your Product Development Strategy

2023-08-0212:40

21: Navigating a complex global regulatory environment to bring medicinal products to market

21: Navigating a complex global regulatory environment to bring medicinal products to market

2023-07-1813:53

20: Safety Reporting Requirements for Marketing in the EU

20: Safety Reporting Requirements for Marketing in the EU

2023-07-0620:11

19: The important role of AI in TMF oversight

19: The important role of AI in TMF oversight

2023-05-2412:06

18: Tackling performance requirements in the more prescriptive world of IVDR

18: Tackling performance requirements in the more prescriptive world of IVDR

2023-04-0513:22

00:00

00:00

1.0x

18: Tackling performance requirements in the more prescriptive world of IVDR

18: Tackling performance requirements in the more prescriptive world of IVDR

PharmaLex Talks